ARTICLE | Clinical News
FDA approves Emmaus' Endari sickle cell therapy
August 4, 2017 4:44 PM UTC
FDA approved Endari L-glutamine (NutreStore, Levoglutamide) from Emmaus Life Sciences Inc. (Torrance, Calif.) to treat sickle cell disease.
The company plans to launch Endari in 4Q17, with an anticipated list price of about $11,000-$18,000 per year...
BCIQ Company Profiles